Connect with us


180 Life Sciences collaborates with pioneer to develop CBD analogue

The company has collaborated with the “father of cannabis” Professor Raphi Mechoulam to identify of HUM-217.



180 Life Sciences collaborates with pioneer to develop CBD analogue

Biotechnology company 180 Life Sciences has identified a CBD analogue that will move forward in clinical development for inflammation and pain. 

Born out of a merger of three companies, 180 Life Sciences is focused on the development of novel drugs that fulfil unmet needs in inflammatory diseases, fibrosis and pain. 

A continuing collaboration since 1998 between the “father of cannabis” Professor Raphi Mechoulam, Hebrew University, Jerusalem, co-founder Sir Marc Feldmann’s Laboratory in Oxford, and 180 Life Sciences’ scientists, has led to the identification of a CBD analogue – HUM-217 – which was selected based on a screen of derivatives of CBD and CBG made by Mechoulam and which will be will be advanced to clinical development for chronic pain and early arthritis.

According to the company, the analogue has a novel composition of matter which would enable patent protection, robust preclinical efficacy in several established mouse models for treating pain and inflammation in vivo, and ease of scalability for GMP manufacturing.

Industry veteran and 180 Life Sciences CEO, Dr Jim Woody, commented: “180 Life Sciences is the merger of three companies – one in Israel with Dr Mechoulam, who was working on cannabinoids, one in Oxford, UK, that was working on anti-inflammatory agents, primarily anti-TNF, and one here in the US that works on a nicotinic acid receptor agonist. 

“A long time ago, Dr Feldmann and I were working together and we were the first ones to ever invent an antibody against TNF. We showed it worked in rheumatoid arthritis and Crohn’s disease, psoriasis and ulcerative colitis, and it is now one of the standards of care called Remicade. There are probably 40 million people treated with anti-TNF so there are now no patients with rheumatoid arthritis in wheelchairs because of that drug and the follow on drugs. 

“However, there are problems with anti-TNF’s because the drug is saving the joints but the pain doesn’t totally go away. So, what we are focusing on is making synthetic cannabinoids that will have the ability to be anti-inflammatory and anti-pain. 

“We have now been able to do that – we selected our lead compound to move ahead and go through IND-Enabling studies. We have already tested our compound in inflammation models – there are animal models of inflammation that can give a good readout on whether this works or not – and we know that the compound is effective in those models. With the way it is constructed, it won’t be psychogenic and it is easily absorbed, so we can actually take enough of it or make it into a pill so, people could use it as opposed to regular cannabis that is made up of maybe 100 or more compounds. 

“We will treat patients who have arthritis and receive anti-TNF, but it doesn’t quite make their pain go away, as you do not want your patients to have to use opioids, which is not very satisfactory. Steroids are another problem because of their side effects – a lot of them cause kidney problems, for example. This pill will be non-addictive, and also quite favourable for the pain. 

“It turns out that there are two TNF-receptors, and one of them is inflammatory and the other one is anti-inflammatory so, down the road, we are going to make specific drugs against each of those to try to get away from the infectious disease complications. So, it is a whole new novel area but Dr Feldmann and I and others are very familiar with the TNF field.”

Dr Woody says that the anlaogue would be added to the regimen of doctors prescribing anti-TNFs as a large clinical trial, possibly all over Europe. Additionally, he says 180 Life Sciences are licensing more compounds from Oxford that have unique abilities to help tissue regrow after is damaged.

“In the cannabinoid area, I think this class of drugs probably has a lot of uses. Certainly, it’s being used in paediatric seizures and things like post-traumatic stress disorder, but these are not clean compounds, they are very complicated. 

“So, I think for the field to move ahead, we need to do what we are doing – making very specific medicines and molecules, so we know what they are, we know how they work, and then we can address many of these other problems because there is a whole range of therapeutics there that will be quite helpful that I think will be tailored for different diseases.”

The company recently raised $15m through private placement, which will fund general corporate purposes, working capital, and the research and development of its programmes which are not funded by grants.

“We raised the funds to accelerate these programmes moving forward. It will almost all go into the projects themselves. We don’t have an office because we’re scattered between Israel and Oxford and Palo Alto and so, we plan to put almost all the money into the programmes and get them to move more quickly.”


Cannaray to drive brand awareness following successful fundraise

Blue Array will be assisting the company in its digital campaigns.



Cannaray to drive brand awareness following successful fundraise
Home » News » CBD » 180 Life Sciences collaborates with pioneer to develop CBD analogue

UK CBD brand, Cannaray has appointed Blue Array to lead its PR strategy and activity for 2022.

The appointment follows the successful completion last month’s groundbreaking £10m funding round. 

The round included major participants including the UK’s largest media-for-equity fund, Channel 4 Ventures – a first-of-its-kind backing in the European cannabis sector – as well as Three Bridges Private Capital and Alpha Blue Ocean.

Head of digital and communications at Cannaray, Jessica Mills, commented: “We are having a fantastic year of growth, bringing Cannaray’s CBD revolution to new consumers across the UK. 

Read more: Channel 4 Ventures joins £10m funding round for CBD company Cannaray

“Since appointing Blue Array to drive our SEO, they have proved to be a valuable agency partner and we are delighted to be deepening our partnership through Digital PR. 

“The Blue Array team brings a huge amount of energy and passion to their approach, and we look forward to working with them moving forwards.”

Head of Digital PR at Blue Array, Jodie Harris, commented: “Cannaray CBD is an inspiring brand and has an ever-growing following. 

“We are thrilled to be in partnership with Cannaray and to focus on delivering the brand’s core messaging whilst ensuring they dominate through organic search for the year ahead. 

“We know this year is big for Cannaray and we are excited to be a part of the journey.”

Cannaray was the first CBD brand to invest in major brand advertising in the UK. In 2021 they began a national television and out of home campaign featuring brand ambassador and UK TV Presenter Claudia Winkleman. 

Blue Array’s Digital PR arm which launched in August last year is tasked to drive awareness campaigns and educate the public about adopting CBD into their lifestyle as well as raise the brand’s visibility through media relations and product promotion.

Continue Reading


New chief technology officer appointed at High Tide  

Greg Fleury has joined the CBD company.



New chief technology officer appointed at High Tide  
Home » News » CBD » 180 Life Sciences collaborates with pioneer to develop CBD analogue

Greg Fleury has been appointed as chief technology officer (CFO) at High Tide.

Fleury will bring over 20 years experience to the role. Fleury will apply his knowledge of developing and managing digital operations teams, web platform design, analytics, search engine optimisation, and e-commerce in the retail, oil and gas, and utilities sectors. 

President and CEOof High Tide, Raj Grover, commented: “It gives me great pleasure to announce the addition of Greg Fleury to High Tide’s executive team. Greg is an avid technological innovator with many years of experience and a track record of success. 

“I plan on working closely with him over the coming months to take the digital and e-commerce components of High Tide’s integrated cannabis ecosystem to new heights.

Read more: Canada’s High Tide to enter UK market with Blessed CBD acquisition

“I would also like to thank Sean Geng for all of his efforts as High Tide’s Chief Technology Officer over the last year. Sean will remain on board with our company as a technology consultant, and I look forward to his continued contributions,” added Mr. Grover.

In Fleury’s prior role as vice president of digital and technology for Edo Japan, a Canadian fast food restaurant chain specialising in Japanese Teppan-style cooking, he led the development of that company’s ordering app, website, data warehouse, and analytics systems.

As CFO, Fleury will be responsible for leading High Tide’s global technology and digital operations, overseeing the development of digital platforms, digital commerce, security, and analytics, as well as managing High Tide’s IT infrastructure.

Read more: Inflation – is it affecting the cannabis market?

Fleury commented: ”I am excited to be joining a company that is as dynamic and fast-growing as High Tide is. Over the past year, High Tide has established itself as an e-commerce leader within the global cannabis space, and I was particularly drawn to the company because of this.

“I am eager to begin working to optimise High Tide’s digital platforms, building on our already-solid footing to keep us at the forefront of the cannabis sector’s technological evolution.”

The Canadian company announced in 2021 that it is making moves to enter the UK CBD market. In October, High Tide acquired Scotland-based Blessed CBD for £9.06m – a step towards solidifying itself as a major player within the global e-commerce marketplace for hemp-derived CBD products. 

As part of the acquisition, Blessed’s founder and CEO, Vithurs Thiru joined the High Tide team as senior manager of research, helping grow High Tide’s CBD business globally.

Continue Reading


Cellular Goods: Amazon’s CBD pilot is helping overcome ad restrictions

Cannabis Wealth speaks to Cellular Goods about advertising and sales restrictions and its appearance on Amazon’s new UK CBD product pilot.



Cellular goods: Amazon's CBD pilot is helping overcome ad restrictions
Home » News » CBD » 180 Life Sciences collaborates with pioneer to develop CBD analogue

Cellular Goods CEO, Anna Chokina, discusses how Amazon’s CBD pilot is helping the company overcome barriers from major online platforms when it comes to advertising and selling cannabinoid products.

The UK has a high demand for cannabinoid-based products. According to a report by the Centre for Medicinal Cannabis, the CBD market generated £690m in annual sales in 2021, and projects that it will reach nearly £1B by 2025.

Estimating the UK CBD market to be one of the largest in the world, the report notes that surveys from Dynata and YouGov indicate between 4 to 6 million UK adults have tried CBD.

Read more: Cellular Goods white paper explores the sustainability of cannabinoid production

CBD companies in the UK struggle to advertise products through usual marketing channels such as Google and other social media sites. This is a problem that does not seem to be moving, says Cellular Goods CEO, Anna Chokina, who suggests the platforms could play a more proactive role in the UK marketplace in their respective fields. 

With the lack of marketing access to these platforms, Chokina highlights that the Amazon marketplace was a natural choice to host Cellular Goods’ products.

Cellular goods: Amazon's CBD pilot is helping overcome ad restrictions

Chokina commented: “There is a considerable demand for products, yet somehow the information flow from the companies that play in this industry to the end customer is quite difficult.

“There is no lack of variety in terms of what’s available in the marketplace, but it’s very hard to understand what the products do and how they work. What is CBD, what is CBG, plant based, non-plant based, biosynthesised? 

Read more: Cellular Goods launches UK’s first CBG face serum

“It can be very hard to understand for the average consumer. It’s very hard as manufacturers and producers not only to sell our products but also to deliver truthful information to the customers about what the industry is and what the products do.”

Amazon approached Cellular Goods to take part in its new pilot trial of CBD products in the UK at the same time the company was discovering the limitations of Google and Meta. The eCommerce giant has already demonstrated that it is not shy about cannabis with its lobbying efforts for reform in the US having already removed cannabis testing from its pre-employment screenings, and now, its new CBD pilot is showing its support for the UK sector. 

“We are quite happy to take part in this pilot because at least this way we have access to the Amazon consumer base that are searching for cannabinoid-based products,” said Chokina. 

Cellular Goods will be featuring a number of its products on the platform, such as its cosmetic Look Better range which includes its new CBG face serum – the UK’s first CBG-based serum to prevent the signs of aging caused by UV light exposure and inflammation.

The company produced research on the anti-inflammatory and antioxidant properties of cannabinoids CBG and CBD, which demonstrated the cannabinoids as contenders for other popular anti-inflammatory and anti-aging ingredients such as retinol and vitamin C serums, whilst also being much kinder for skin.


Chokina continued: “This was Cellular Goods way of ensuring that people who search for cannabinoid-based products were aware of our brand. As a startup, you have to look for ways to get your product out there, to get your name out.”

Many customers may not be aware of some of the cosmetic benefits of cannabinoids, and Chokina emphasises that customer education is key for the CBD market.

“I think consumer education is very important. I think one side effect from Meta and Google not taking a more proactive approach to allow companies to advertise freely or to trade freely on their platforms, is the fact that consumers are clueless,” said Chokina.

“They do not know the difference between CBD or CBG, they don’t know the amazing promises these ingredients can bring. 

“So, we as the brand would like to become that voice that drives clarity, and hopefully, in time, the credibility will come with our name as well, that we’re only going to put the products in the market if they’re justified from the scientific standpoint. 

“Science is very much who we are, so we want to make sure that what we bring is substantiated and it’s consistent as well.”

Chokina highlights that Cellular Goods has undertaken a 360-degree media campaign that includes billboards across London and Manchester, which will help drive customers to the Amazon platform as well as its own website marketplace.

Chokina said: “We have partnerships with Conde Nast with GQ with Vogue. So, there is a lot of influencer strategy involved as well. 

“We’re working with bloggers and advertising, so, we have limitations on Meta and Google, but it doesn’t mean that the customers are not going to know about us. I don’t think one campaign is going to educate the market to get the customer base and get the sales growing. It’s just the start.

“We are pleased and humbled to be approached by Amazon because it’s also a sign that the industry is developing. It’s a sign that the wind is turning. So, it is definitely very positive for us. We are very much focused on our customers. 

“If our customers prefer to shop, for instance, in some of the retail stores or in the pure play beauty stores, online that that’s where we would like to be because we are very much focused on making it easy for them to buy us.

“As part of our expansion to Europe and beyond, this is also going to be an integral part of our go-to market. What Amazon is doing is a sign of thriving, and I hope that the other big companies are going to follow suit and then we can advance and push the industry.”

Continue Reading
Sign up for the Cannabis Wealth newsletter

Recent Posts